U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT07522970) titled 'A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LG-0317 in Healthy Participants' on April 03.
Brief Summary: This study is the first administration of LG-0317 to humans. The purpose of the study is to evaluate safety/tolerability and pharmacokinetics in healthy subjects. The intention of this study is to provide confidence in the safety of the molecule to inform progression to further proof-of-concept studies.
Study Start Date: April 14
Study Type: INTERVENTIONAL
Condition:
Healthy Volunteers
Intervention:
DRUG: LG-0317
Subjects are planned to be dosed in oral tablet, with single and mu...